ISDA has today published the ISDA Master Regulatory Disclosure Letter (MRDL). The MRDL is a form of letter that is intended to allow market participants to exchange information regarding counterparty status as required under relevant regulatory regimes.
The MRDL currently provides for the exchange of counterparty status information in relation to EMIR (as amended by EMIR REFIT) by appending a modified form of the previous ISDA EMIR Classification Letter as Appendix A (European Union). It is anticipated that the MRDL will be updated or supplemented over time through the addition of new appendices to accommodate, for example, increased granularity of data or extension of asset class or geography.
The MRDL and accompanying guidance note can be found here.
A webinar explaining the impact of the EMIR REFIT from a buy-side perspective can be found here.
An explanatory note on the application of EMIR REFIT to Alternative Investment Funds can be found here.
Latest
ISDA AGM Studio: Darcy Bradbury & Tyler Wellensiek
Darcy Bradbury, ISDA board member and managing director at D. E. Shaw, and Tyler Wellensiek, managing director and global head of market structure at BlackRock, speaks with Chris Young, ISDA’s head of US public policy, about how the post‑crisis regulatory...
Response to ESMA Guarantees
On April 30, ISDA responded to the European Securities and Markets Authority (ESMA) consultation paper on guarantees as central counterparty (CCP) collateral and certain aspects of CCP investment policy. ISDA broadly supports ESMA’s proposed draft regulatory technical standards (RTS) to...
ISDA AGM Studio: Jenny Cosco and Jason Granet
Jenny Cosco, global head of government relations and regulatory strategy at LSEG, and Jason Granet, chief investment officer at BNY, speak with Tara Kruse, ISDA’s global head of derivative products and infrastructure, about how firms can manage liquidity pressures during...
Updated OTC Derivatives Compliance Calendar
ISDA has updated its global calendar of compliance deadlines and regulatory dates for the over-the-counter (OTC) derivatives space.